A triplet of Keytruda failures
Merck sees clinical setbacks in Keylynk-008, Leap-001 and Keyvibe-002.
SABCS 2023 – SERDs square off in combinations
Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?
Crispr abandons first-generation Car-T projects
The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.
Roche seeks alpha to defeat Novartis
With inavolisib’s pivotal front-line win Roche reckons it can knock out Novartis’s Piqray.
ESMO Asia 2023 – deaths raise doubts about Merus’s Rybrevant challenger
Merus still hopes for a future for MCLA-129, but the doors are closing.
Argenx’s efforts to Advance fall flat
Failure of a subcutaneous formulation of Vyvgart raises questions about the drug’s future in primary immune thrombocytopenia and beyond.
